
|Articles|February 27, 2014
- NSCLC (Issue 2)
- Volume 2
- Issue 1
Crizotinib Resistance in ALK-Positive Lung Cancer
Author(s)Alice T. Shaw, MD, PhD
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer
Advertisement
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer.
Learn more about thetreatment of ALK-positive lung cancer > >
Articles in this issue
almost 12 years ago
Clinical Update: ALK-Positive NSCLCalmost 12 years ago
PD-L1 as a Biomarker for Immunotherapy Agents in Lung Canceralmost 12 years ago
Treating Older Patients With NSCLCalmost 12 years ago
Treatment of Elderly Patients With NSCLCalmost 12 years ago
Current Challenges in Molecular Testing in NSCLCalmost 12 years ago
Individualized Maintenance Therapy for NSCLCalmost 12 years ago
Frontline Treatment Considerations in Non-Small Cell Lung CancerAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















